Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Henschke

Internal Medicine Newington, NH Doctor of Osteopathy

NPI 1922092667 CMS profile 268996

2064 Woodbury Ave, Suite 102, Newington, NH 03801

Open in the dashboard

General payments

$113,817

265 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Henschke of Newington, NH is reported in the CMS Open Payments database as having received $113,817 across 265 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $432 7
2024 General $2,558 10
2023 General $6,843 15
2022 General $33,412 69
2021 General $42,907 82
2020 General $20,639 41
2019 General $7,025 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Henschke
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mark Henschke were reported at $432. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mark Henschke Internal Medicine median Middle half National median
2019 $7,025 $159 $48–$570 $163
2020 $20,639 $119 $33–$402 $114
2021 $42,907 $135 $37–$521 $132
2022 $33,412 $141 $42–$496 $149
2023 $6,843 $149 $45–$519 $160
2024 $2,558 $154 $47–$537 $164
2025 $432 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $82,096 133 payments
  2. Allergan Inc. $22,280 36 payments
  3. Novartis Pharmaceuticals Corporation $4,780 15 payments
  4. Janssen Pharmaceuticals, Inc $884 13 payments
  5. GlaxoSmithKline, LLC. $799 12 payments
  6. AstraZeneca Pharmaceuticals LP $614 7 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $325 7 payments
  8. Teva Pharmaceuticals USA, Inc. $265 2 payments
  9. E.R. Squibb & Sons, L.L.C. $204 6 payments
  10. Merck Sharp & Dohme Corporation $176 2 payments
  11. Other $1,393 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $96,560 48 payments
  2. Food and Beverage $8,017 154 payments
  3. Travel and Lodging $5,904 62 payments
  4. Consulting Fee $3,336 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY Neuroscience $76,512 116 payments
  2. UBRELVY Neuroscience $20,386 33 payments
  3. QULIPTA $13,911 26 payments
  4. ENTRESTO $4,780 15 payments
  5. XARELTO $645 11 payments
  6. NUCALA $340 3 payments
  7. JARDIANCE $325 7 payments
  8. BREZTRI $253 2 payments
  9. FARXIGA $244 4 payments
  10. TRELEGY ELLIPTA $218 5 payments
  11. Other $3,102 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$43,481

Medicare's payments for the services billed

Medicare patients

13

Average age 71

Services billed

35

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Osteoporosis 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $2,357
$2,357 — —
NUCALA
  • GlaxoSmithKline, LLC. $102
$102 — —
EVKEEZA
  • Regeneron Healthcare Solutions, Inc. $22
$22 — —
RYBELSUS
  • Novo Nordisk Inc $20
$20 — —
Ozempic
  • Novo Nordisk Inc $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record